Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib

Solid Tumor Clinical Trial

— AME  

Official title:

An Open-Label, Non-Randomized, Phase I Study to Assess the Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02986100
• Other study ID #: CO-338-045
• Secondary ID: 2015-004394-32
• Status: Completed
• Phase: Phase 1
• Start date: November 2016
• Est. completion date: September 2018

Study information

• Verified date: June 2023
• Source: zr Pharma & GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize the mass balance, absorption, metabolism, and elimination pathways of orally administered [14C] rucaparib followed by cycle by cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation

Description:

This is a Phase 1, open-label, non-randomized, mass balance study in patients with histologically or cytologically confirmed advanced solid tumors. Approximately 6 patients will be enrolled. The study will consist of 2 parts: a mass balance part (Part I) and a rucaparib treatment part (Part II).

Each patient will receive a single oral dose of 600 mg [14C] rucaparib (approximately 140 µCi) in the fasted state. Patients will be confined at the study site for the collection of blood samples and excreta for a maximum of 13 days, from Day -1. The patient can be discharged sooner than Day 13, if the discharge criteria are met. If the cumulative recovery of radioactivity exceeds 90% of the administered dose or if radioactivity in urine and feces is < 1% of the administered dose over a 24 hour period on two consecutive days, as determined by quick counts.

In Part II, the treatment with rucaparib in 28-day cycles will continue until progression of disease, unacceptable toxicity, or other reason for discontinuation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: September 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed advanced solid tumor

• Part II only: Have a known deleterious BRCA1/2 mutation (germline or somatic) as determined by a local or central laboratory

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Adequate bone marrow, renal, and liver function

Exclusion Criteria:

• Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, or angiogenesis inhibitors within 14 days prior to Day 1

• Participation in a trial involving administration of [14C]-labeled compound(s) within the last 6 months prior to Day 1

• Arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within the last 3 months prior to Screening

• Pre-existing duodenal stent, recent or existing bowel obstruction, and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib

• Untreated or symptomatic central nervous system (CNS) metastases

• Evidence or history of bleeding disorder

• Participation in another investigational drug trial within 14 days prior to Day 1 (or 5 times the half-life of the drug, whichever is longer) or exposure to more than three new investigational agents within 12 months prior to Day 1

• Acute illness (eg, nausea, vomiting, fever, diarrhea) within 14 days prior to Day 1, unless mild in severity and approved by the Investigator and Sponsor's/designated medical representative

• Active second malignancy

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• C-14 labeled Rucaparib
Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and [14C]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of [14C]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of [14C]-rucaparib
• Rucaparib
200 & 300 mg tablet

Locations

Country	Name	City	State
Hungary	PRA Magyarország Kft.	Budapest	Rottenbiller Utca 13

Sponsors (1)

Lead Sponsor	Collaborator
zr Pharma & GmbH

Country where clinical trial is conducted

Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To evaluate the antitumor activity of rucaparib in BRCA mutated solid tumors based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1	Response will be determined using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and tumor markers per applicable criteria for a given tumor type	Cycle 1 Day 1 until progression of disease, unacceptable toxicity, or discontinuation for other reasons
Primary	Pharmacokinetics of 14C-labeled rucaparib (radioactivity in whole blood and plasma): tmax	Time to peak concentration (tmax)	Days 1-13
Primary	Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): Cmax	peak (maximum) concentration (Cmax)	Days 1-13
Primary	Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): t1/2	Elimination half-life (t1/2)	Days 1-13
Primary	Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): AUC	Area under curve (AUC)	Days 1-13
Primary	Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): CL/F	Oral clearance (CL/F)	Days 1-13
Primary	Pharmacokinetics of 14C-labeled rucaparib(Radioactivity in whole blood and plasma): V/F	Apparent volume of distribution (V/F)	Days 1-13
Primary	Excretion rate of 14C-labeled rucaparib(radioactivity in feces)	Percent of dose excreted in feces	Days 1-13
Primary	Excretion rate of 14C-labeled rucaparib(radioactivity in urine)	Percent of dose excreted in urine	Days 1-13
Primary	Pharmacokinetics of rucaparib (in urine): CLR	Renal clearance (CLR)	Days 1-13
Primary	Excretion rate of 14C-labeled rucaparib(radioactivity in vomit, if applicable)	Percent of dose in vomit, if applicable	Days 1-13
Primary	Metabolite identification of rucaparib in plasma, urine and feces		Days 1-13
Primary	Cumulative whole blood:plasma ratio calculated for Cmax	peak concentration (Cmax)	Days 1-13
Primary	Cumulative whole blood:plasma ratio calculated for AUC0-tlast	AUC from time zero to the last time point with concentration above the lower limit of quantitation (AUC0-last)	Day 1-13
Primary	Cumulative whole blood:plasma ratio calculated for AUCinf	AUC from time zero to infinity (AUCinf)	Day 1-13
Secondary	Tolerability and safety of rucaparib assessed by incidence of Adverse Events (AEs), clinical laboratory abnormalities, and dose modifications	Incidence of Adverse Events (AEs), clinical laboratory abnormalities, and dose modifications	From cycle 1 Day 1 until radiologically confirmed disease progression, death, or initiation of subsequent treatment whichever comes first up to 52 weeks